Caggana M - Search Results

1

A prospective study of hprt mutant and mutation frequencies in treated cancer patients.

Caggana M, Liber HL, Coleman CN, Mauch P, Clark JR, Kelsey KT. Caggana M, et al. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec;1(7):573-80. Cancer Epidemiol Biomarkers Prev. 1992. PMID: 1302570

2

In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients.

Caggana M, Liber HL, Mauch PM, Coleman CN, Kelsey KT. Caggana M, et al. Environ Mol Mutagen. 1991;18(1):6-13. doi: 10.1002/em.2850180103. Environ Mol Mutagen. 1991. PMID: 1713845

3

In vivo exposure of human lymphocytes to technetium-99m in nuclear medicine patients does not induce detectable genetic effects.

Kelsey KT, Donohoe KJ, Memisoglu A, Baxter B, Caggana M, Liber HL. Kelsey KT, et al. Among authors: caggana m. Mutat Res. 1991 Dec;264(4):213-8. doi: 10.1016/0165-7992(91)90081-e. Mutat Res. 1991. PMID: 1723502

4

Single-strand conformation polymorphisms can be used to detect T cell receptor gene rearrangements: an application to the in vivo hprt mutation assay.

Caggana M, Benjamin MB, Little JB, Liber HL, Kelsey KT. Caggana M, et al. Mutagenesis. 1991 Sep;6(5):375-9. doi: 10.1093/mutage/6.5.375. Mutagenesis. 1991. PMID: 1795641

5

Genotoxic and mutagenic effects of the diagnostic use of thallium-201 in nuclear medicine.

Kelsey KT, Donohoe KJ, Baxter B, Memisoglu A, Little JB, Caggana M, Liber HL. Kelsey KT, et al. Among authors: caggana m. Mutat Res. 1991 Jul;260(3):239-46. doi: 10.1016/0165-1218(91)90032-h. Mutat Res. 1991. PMID: 1870614

6

Sister chromatid exchange frequency in Hodgkin's disease patients with elevated in vivo hprt mutant frequencies.

Caggana M, Kelsey KT. Caggana M, et al. Carcinogenesis. 1991 Nov;12(11):2141-5. doi: 10.1093/carcin/12.11.2141. Carcinogenesis. 1991. PMID: 1934301

7

Mutagenesis after cancer therapy.

Kelsey KT, Caggana M, Mauch PM, Coleman CN, Clark JR, Liber HL. Kelsey KT, et al. Among authors: caggana m. Environ Health Perspect. 1993 Oct;101 Suppl 3(Suppl 3):177-84. doi: 10.1289/ehp.93101s3177. Environ Health Perspect. 1993. PMID: 8143613 Free PMC article.

8

Associations between ERCC2 polymorphisms and gliomas.

Caggana M, Kilgallen J, Conroy JM, Wiencke JK, Kelsey KT, Miike R, Chen P, Wrensch MR. Caggana M, et al. Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):355-60. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11319176

9

Rapid, efficient method for multiplex amplification from filter paper.

Caggana M, Conroy JM, Pass KA. Caggana M, et al. Hum Mutat. 1998;11(5):404-9. doi: 10.1002/(SICI)1098-1004(1998)11:5<404::AID-HUMU8>3.0.CO;2-S. Hum Mutat. 1998. PMID: 9600459

10

The allele frequency of mutations in four genes that confer enhanced susceptibility to venous thromboembolism in an unselected group of New York State newborns.

Conroy JM, Trivedi G, Sovd T, Caggana M. Conroy JM, et al. Among authors: caggana m. Thromb Res. 2000 Aug 15;99(4):317-24. doi: 10.1016/s0049-3848(00)00254-1. Thromb Res. 2000. PMID: 10963782

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters